Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079880 | 0.78 | USP2 (0.82) | USP2POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13180853 | 0.70 | LMNA (0.70) | POLBKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL7495037 | 0.68 | LMNA (0.48) | POLBPDE4DKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL24029049 | 0.67 | POLB (0.66) | POLBPDE4DKMT2AMEN1ALDH1A1 | |
| SCHEMBL19079673 | 0.67 | HTT (0.58) | POLBKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL19079691 | 0.66 | PDE4D (1.00) | POLBPDE4DSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15503867 | 0.66 | USP2 (0.78) | USP2POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL19079694 | 0.66 | PDE4D (0.76) | USP2POLBPDE4DSMN1; SMN2ALDH1A1 | |
| SCHEMBL9725963 | 0.65 | ALDH1A1 (0.67) | USP2POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL19079793 | 0.65 | ALDH1A1 (0.78) | USP2POLBPDE4DKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | USP2 758/4885POLB 2192/4885PDE4D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.